Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013)
Relmada Therapeutics (RLMD) reported FCF Margin of 493.19% for Q4 2013, down 56285.0% year-over-year from N/an in Q4 2012, and down 293.28% on a QoQ basis from 125.4% in Q1 2013.
Relmada Therapeutics (RLMD) has 2 years of FCF Margin data on file, last reported at 493.19% in Q4 2013.
- Quarterly FCF Margin fell 56285.0% year-over-year to 493.19% in Q4 2013, while the trailing twelve-month figure through Nov 2013 was 249.81% (changed N/A YoY) and the FY2013 annual result came in at 196.12%, down 10086.0% from the prior year.
- FCF Margin declined to 493.19% in Q4 2013 per RLMD's latest filing, from 125.4% in the prior quarter.
- Across five years, FCF Margin topped out at 69.66% in Q4 2012 and bottomed at 496.5% in Q2 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -493.19% |
| Feb 28, 2013 | -125.40% |
| Nov 30, 2012 | 69.66% |
| Aug 31, 2012 | -220.73% |
| May 31, 2012 | -496.50% |